留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

唑来膦酸对老年性椎体压缩骨折患者椎体成形术后骨密度的影响

饶敏杰 李亦男 张功恒 袁晓军 甘心荣 徐文华 曹盛生

饶敏杰, 李亦男, 张功恒, 袁晓军, 甘心荣, 徐文华, 曹盛生. 唑来膦酸对老年性椎体压缩骨折患者椎体成形术后骨密度的影响[J]. 中华全科医学, 2021, 19(3): 383-386. doi: 10.16766/j.cnki.issn.1674-4152.001816
引用本文: 饶敏杰, 李亦男, 张功恒, 袁晓军, 甘心荣, 徐文华, 曹盛生. 唑来膦酸对老年性椎体压缩骨折患者椎体成形术后骨密度的影响[J]. 中华全科医学, 2021, 19(3): 383-386. doi: 10.16766/j.cnki.issn.1674-4152.001816
RAO Min-jie, LI Yi-nan, ZHANG Gong-heng, YUAN Xiao-jun, GAN Xin-rong, XU Wen-hua, CAO Sheng-sheng. Effect of zoledronic acid combined with percutaneous vertebroplasty on osteoporotic compression fractures in the elderly patients[J]. Chinese Journal of General Practice, 2021, 19(3): 383-386. doi: 10.16766/j.cnki.issn.1674-4152.001816
Citation: RAO Min-jie, LI Yi-nan, ZHANG Gong-heng, YUAN Xiao-jun, GAN Xin-rong, XU Wen-hua, CAO Sheng-sheng. Effect of zoledronic acid combined with percutaneous vertebroplasty on osteoporotic compression fractures in the elderly patients[J]. Chinese Journal of General Practice, 2021, 19(3): 383-386. doi: 10.16766/j.cnki.issn.1674-4152.001816

唑来膦酸对老年性椎体压缩骨折患者椎体成形术后骨密度的影响

doi: 10.16766/j.cnki.issn.1674-4152.001816
基金项目: 

江西省卫生计生委科技计划课题 20197495

详细信息
    通讯作者:

    曹盛生,E-mail: yichunhot@126.com

  • 中图分类号: R683.2  R445.4

Effect of zoledronic acid combined with percutaneous vertebroplasty on osteoporotic compression fractures in the elderly patients

  • 摘要:   目的  探讨唑来膦酸对老年性骨质疏松椎体压缩骨折患者椎体成形术后骨密度、骨代谢的影响,为临床治疗提供依据。  方法  选取2019年1月—2019年12月在宜春市人民医院骨科应用经皮椎体成形术治疗的老年骨质疏松椎体压缩性骨折患者92例,采用数字随机法将92例患者分为对照组和治疗组,对照组48例,治疗组44例。对照组患者行椎体成形术后给予骨化三醇联合维生素D治疗;治疗组患者行椎体成形术后给予骨化三醇、维生素D及唑来膦酸治疗。比较2组患者治疗前、治疗后的VAS评分及Oswestry功能障碍指数评分(ODI);并比较2组患者治疗前、治疗后的腰椎骨密度及骨钙素(BGP)指标变化。  结果  所有患者均顺利完成椎体成形手术。治疗前,2组患者VAS、ODI、腰椎骨密度、骨钙素差异均无统计学意义(均P>0.05);治疗后,2组患者VAS、ODI均明显下降(均P<0.05),且治疗组明显优于对照组(均P<0.05)。治疗前,2组患者腰椎骨密度、血清骨钙素差异无统计学意义(均P>0.05);治疗后,2组患者腰椎骨密度、血清骨钙素均明显升高(均P<0.05),且治疗组明显优于对照组(均P<0.05)。  结论  唑来膦酸联合椎体成形术治疗老年骨质疏松椎体压缩性骨折疗效良好,能有效改善患者骨质疏松症状,提高患者骨密度及骨代谢指标。

     

  • 表  1  2组老年骨质疏松性椎体压缩骨折患者一般情况比较  (x ±s)

    组别 例数 性别(例) 平均年龄
    (岁)
    随访时间
    (月)
    男性 女性
    治疗组 48 25 23 72.56±3.24 24.29±4.24
    对照组 44 23 21 70.82±6.08 23.89±7.55
    统计量 0.513a 0.461b 0.488b
    P 0.812 0.772 0.610
    注:a为χ2值,bt值。
    下载: 导出CSV

    表  2  2组老年骨质疏松性椎体压缩骨折患者VAS评分结果  (x ±s,分)

    组别 例数 VAS评分 t P
    治疗前 治疗后
    治疗组 48 8.22±1.31 2.25±1.19 68.625 <0.001
    对照组 44 8.09±1.22 2.89±2.46 40.562 <0.001
    t 0.147 9.882
    P 0.223 <0.001
    下载: 导出CSV

    表  3  2组老年骨质疏松性椎体压缩骨折患者ODI评分结果  (x ±s,分)

    组别 例数 ODI评分 t P
    治疗前 治疗后
    治疗组 48 74.48±14.24 21.28±17.05 27.891 <0.001
    对照组 44 75.37±16.92 24.19±10.66 18.639 <0.001
    t 0.126 8.812
    P 0.158 <0.001
    下载: 导出CSV

    表  4  2组老年骨质疏松性椎体压缩骨折患者腰椎骨密度结果  (x ±s,g/cm2)

    组别 例数 腰椎(L1~4) t P
    治疗前 治疗后
    治疗组 48 0.69±0.08 0.83±0.37 5.849 0.014
    对照组 44 0.68±0.11 0.81±0.46 3.716 0.022
    t 0.418 2.253
    P 0.652 <0.001
    下载: 导出CSV

    表  5  2组老年骨质疏松性椎体压缩骨折患者骨钙素结果  (x ±s,ng/mL)

    组别 例数 骨钙素 t P值
    治疗前 治疗后
    治疗组 48 5.58±0.35 10.15±1.92 22.145 <0.001
    对照组 44 5.54±0.44 8.22±1.07 16.272 <0.001
    t 0.426 7.298
    P 0.261 <0.001
    下载: 导出CSV
  • [1] ZHU Y, CHENG J, YIN J, et al. Therapeutic effect of kyphoplasty and balloon vertebroplasty on osteoporotic vertebral compression fracture: a systematic review and meta-analysis of randomized controlled trials[J]. Medicine, 2019, 98(45): e17810. doi: 10.1097/MD.0000000000017810
    [2] SUN X, LIU X, WANG J, et al. The effect of early limited activity after bipedicular percutaneous vertebroplasty to treat acute painful osteoporotic vertebral compression fractures[J]. Pain Phy, 2020, 23(1): E31-E40. http://www.researchgate.net/publication/339067118_The_Effect_of_Early_Limited_Activity_after_Bipedicular_Percutaneous_Vertebroplasty_to_Treat_Acute_Painful_Osteoporotic_Vertebral_Compression_Fractures
    [3] 南运东. 唑来膦酸联合钙剂、阿法骨化醇防治老年骨质疏松脊柱压缩骨折患者PVP术后再骨折[J]. 颈腰痛杂志, 2019, 40(4): 553-554. doi: 10.3969/j.issn.1005-7234.2019.04.042
    [4] BUCHBINDER R, JOHNSTON R V, RISCHIN K J, et al. Percutaneous vertebroplasty for osteoporotic vertebral compression fracture[J]. Cochrane Database Syst Rev, 2018, 11(11): CD006349.
    [5] 石晨, 程安源. PKP联合唑来膦酸治疗骨质疏松性椎体压缩骨折的疗效分析[J]. 中国骨与关节损伤杂志, 2019, 34(7): 709-711. https://www.cnki.com.cn/Article/CJFDTOTAL-GGJS201907011.htm
    [6] VISWANNATHAN M, REDDY S, BERKMAN N, et al. Screening to prevent osteoporotic fractures: an evidence review for the U.S. preventive services task force[J]. Rockville, 2018, 15(6): 35-39. http://www.ncbi.nlm.nih.gov/pubmed/29946734
    [7] 李正, 付军. 唑来膦酸和特立帕肽对预防椎体成形术后再发骨折的疗效比较[J]. 中国骨质疏松杂志, 2019, 25(7): 1002-1005. doi: 10.3969/j.issn.1006-7108.2019.07.024
    [8] ZHU J, ZHANG K, LUO K, et al. Mineralized collagen modified polymethyl methacrylate bone cement for osteoporotic compression vertebral fracture at 1-year follow-up[J]. Spine, 2019, 44(12): 827-838. doi: 10.1097/BRS.0000000000002971
    [9] 马建华, 王庆雷. 高粘度骨水泥对不同程度骨质疏松性椎体压缩性骨折经皮椎体成形术的疗效影响及其弥散分析[J]. 中国基层医药, 2018, 25(21): 2721-2725. doi: 10.3760/cma.j.issn.1008-6706.2018.21.001
    [10] WANG F, WANG L F, MIAO D C, et al. Which one is more effective for the treatment of very severe osteoporotic vertebral compression fractures: PVP or PKP?[J]. J Pain Res, 2018, 11(6): 2625-2631. http://www.ncbi.nlm.nih.gov/pubmed/30464581
    [11] ISAWA M, KARAKAWA A, SAKAI N, et al. Biological effects of anti-RANKL antibody and zoledronic acid on growth and tooth eruption in growing mice[J]. Sci Rep, 2019, 9(1): 19895. doi: 10.1038/s41598-019-56151-1
    [12] 钟杰林, 蔡迎, 金成浩, 等. 唑来膦酸对老年女性骨质疏松性椎体压缩性骨折的疗效分析[J]. 中国中西医结合外科杂志, 2019, 25(3): 331-336. doi: 10.3969/j.issn.1007-6948.2019.03.017
    [13] 马晓勇, 高飞, 万英辉, 等. 绝经后骨质疏松性骨折治疗与再骨折的关系研究[J]. 河北医药, 2020, 42(2): 261-264. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYZ202002025.htm
    [14] AGARWALA S, VIJAYVARGIVA M. Single dose therapy of zoledronic acid for the treatment of transient osteoporosis of hip[J]. Ann Rehabil Med, 2019, 43(3): 314-320. doi: 10.5535/arm.2019.43.3.314
    [15] BAUER D C. Review: long-term alendronate or zoledronic acid reduces fractures in postmenopausal women with osteoporosis[J]. Ann Intern Med, 2019, 171(4): JC22. doi: 10.7326/ACPJ201908200-022
    [16] 张世浩, 苏菲, 王洪, 等. 唑来膦酸与阿仑膦酸钠预防PKP术后再骨折的效果分析[J]. 中国骨与关节损伤杂志, 2019, 34(11): 1125-1127. doi: 10.7531/j.issn.1672-9935.2019.11.002
    [17] PFLIMLIN A, GOURNAY A, DELABRIÈRE I, et al. Secondary prevention of osteoporotic fractures: evaluation of the lille university hospital's fracture liaison service between January 2016 and January 2018[J]. Osteoporos Int, 2019, 30(9): 1779-1788. doi: 10.1007/s00198-019-05036-0
    [18] 赵成毅, 李青, 梁道臣, 等. 椎体成形术后应用唑来膦酸联合维生素K2治疗老年性椎体压缩骨折[J]. 中华关节外科杂志(电子版), 2018, 12(3): 433-437. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHGJ201803025.htm
    [19] HAN D, LONG A, WANG J, et al. Effect of cervus and cucumis polypeptide combined with zoledronic acid on bone metabolic biochemical markers in glucocorticoids-induced osteoporosis patients[J]. Saudi J Biol Sci, 2019, 26(5): 1027-1031. doi: 10.1016/j.sjbs.2019.04.010
    [20] WONG S P Y, MOK C C. Update on symptomatic treatment of acute vertebral compression fracture[J]. J Clin Rhe, 2019, 19(2): 47-52. doi: 10.1142/S2661341719300039
    [21] HOSOGANE N, NOJIRI K, SUZUKI S, et al. Surgical treatment of osteoporotic vertebral fracture with neurological deficit-a nationwide multicenter study in Japan[J]. Spine Surg Relat Res, 2019, 3(4): 361-367. doi: 10.22603/ssrr.2019-0004
    [22] LEE B G, CHOI J H, KIM D Y, et al. Risk factors for newly developed osteoporotic vertebral compression fractures following treatment for osteoporotic vertebral compression fractures[J]. Spine J, 2019, 19(2): 301-305. doi: 10.1016/j.spinee.2018.06.347
  • 加载中
表(5)
计量
  • 文章访问数:  110
  • HTML全文浏览量:  83
  • PDF下载量:  1
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-04-26
  • 网络出版日期:  2022-02-19

目录

    /

    返回文章
    返回